NewcelX Ltd. (NCEL) stock
Close on Nov 20, 2026Market cap $12.19MP/E 1.2Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $12.19M
- P/E ratio
- 1.2
- Price to sales
- –
- Price to book
- 2.02
- Dividend yield
- –
- Free cash flow yield
- -22.76%
Fundamentals
- Net income
- -$8.30M
- EPS, diluted
- $2.16
- Free cash flow
- -$2.77M
Trading
- Previous close
- $2.69
- Open
- $2.63
- Day's range
- $2.45 – $2.63
- Volume
- 5,727
- Average volume (20 days)
- 26,993
- Beta (5 years)
- 0.83
- 52-week range
- $1.83 – $5.12
- RSI (14 days)
- 43.4
- Volatility (1 year)
- 101.5%
- Relative volume
- 0.44×
- WACC
- 9.2%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.
| Period | NCEL | S&P 500 | Difference | NCEL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.7% | -10.3% | +7.6 pts | ||
| 3 months | -24.6% | -9.3% | −15.3 pts | ||
| Year to date | +33.7% | +1.9% | +31.7 pts | ||
| 1 year | -19.4% | +6.9% | −26.2 pts | ||
| 3 years | -98.6% | +57.5% | −156.0 pts | -75.7% | +16.3% |
| 5 years | -99.7% | +57.3% | −157.0 pts | -68.2% | +9.5% |
Nine years at a glance
Fiscal years 2017 to 2025, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NewcelX filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About NewcelX
Pharmaceutical Preparations
NewcelX Ltd. is a clinical-stage biopharmaceutical enterprise specializing in the development and manufacture of proprietary, allogeneic, off-the-shelf cell therapy products. Utilizing a proprietary technology platform designed for expanding and differentiating human embryonic stem cells (hESCs) into functional cells, the firm advances regenerative medicine candidates. Its clinical-stage pipeline features therapeutic programs such as NCEL-101 and AstroRx. Because its candidates remain in the clinical development and evaluation phases, the company does not yet market commercial products or generate commercial revenue, aiming ultimately to serve patients and healthcare providers through clinical collaborations and specialized medical partnerships.
Company profile, executives and historyNewcelX stock: common questions
What is NewcelX's stock price?
NCEL closed at $2.54 on Nov 20, 2026, down 5.58% on the day. Over the past 52 weeks it traded between $1.83 and $5.12.
What is NewcelX's market cap?
NewcelX was worth $12.19M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.
What is NCEL's P/E ratio?
NCEL trades at 1.2 times earnings, based on diluted earnings per share of $2.16 over fiscal 2025.
Does NewcelX pay a dividend?
No. NewcelX has not paid a cash dividend over the last twelve months.
How has NCEL stock performed over the past year?
Including dividends, NCEL returned -19.4% over the past year, against +6.9% for the S&P 500.
How many NCEL shares are sold short?
0M shares were sold short at the latest FINRA report, 0.65% of the float, or 1.0 days of average trading volume.
Who are NewcelX's competitors?
Companies most similar to NewcelX by business, industry and size include CELU, LGVN, NBP, XTLB, OCS.
See a number that looks wrong?